Abstracts
Please find a list of abstracts the PRCSG has completed below.
View our Authorship Policy and PRINTO and PRCSG Publication Policy
Article Author(s) Journal Year
Pharmacokinetics of Upadacitinib in Pediatric Patients with Polyarticular Course Juvenile Idiopathic Arthritis Yuli Qian, Anna Schmagel, Shuai Hao, Gerd Horneff, Hermine I Brunner, Heidi S Camp, Wei Liu, Mohamed-Eslam Mohamed Annals of the Rheumatic Diseases 2023;82:666-667. 2023
Safety and Efficacy of Upadacitinib for Pediatric Patients With Polyarticular Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-label, Phase 1 Trial Hermine Brunner, Gerd Horneff, Ivan Foeldvari, Jordi Anton, Mohamed-Eslam Mohamed, Yuli Qian, Kristina Unnebrink, Shuai Hao, Heidi Camp, Nasser Khan, Anna Shmagel Annals of the Rheumatic Diseases 2023;82:108-109. 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results From the Extension of the JUNIPERA Trial N Ruperto, I Foeldvari, E Alexeeva, NA Ayaz, G Schulert, S Ozen, A Popov, A Ramanan, C Scott, B Sozeri, E Zholobova, S Chakraborty, X Zhu, R Martin, S Whelan, S Kaur, L Pricop, DJ Lovell, A Martini, HI Brunner Ann Rheum Dis. 2023;82(1):154-160. 2023
Impact of tofacitinib treatment on height in juvenile idiopathic arthritis Hermine Brunner, Halley Wasserman, Michelle Saul, Douglas Robinson, Edward Nagy, Annette Diehl, Mahta Mortezavi Annals of the Rheumatic Diseases 2023;82:673-674. 2023
Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks Nicolino Ruperto, Daniel J Lovell, Sarah Ringold, Xie L. Xu, Jocelyn H. Leu, Edwin Lam, Yuhua Wang, Alberto Martini, Hermine Brunner Arthritis Rheumatol. 2023; 75 (suppl 9). 2023
Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting Pamela F. Weiss, Nicolino Ruperto, Erhard Quebe-Fehling, Alexis Shew, Luminita Pricop, Christelle Pieterse, Hermine Brunner Arthritis Rheumatol. 2023; 75 (suppl 9). 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial Hermine Brunner, Diego Oscar Viola, Richard Dimelow, Inmaculada Calvo Penadés, Christel Wilkinson, Juan Cruz Rizo Rodriguez, Alina Boteanu, Sylvia Kamphuis, Kirsten Minden, Gerd Horneff, Jordi Anton, Masaaki Mori, Yuichi Yamasaki, Jose Miyar Olaiz, Rebecca Marino, Andre van Maurik, Mohamed Okily, Emad Yanni, Paul WIlde Arthritis Rheumatol. 2023; 75 (suppl 9). 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial Hermine Brunner, Ivan Foeldvari, Ekaterina Alexeeva, Nuray Aktay Ayaz, Grant Schulert, Seza Ozen, Artem Popov, Athimalaipet V Ramanan, Christiaan Scott, Betul Sozeri, Elena Zholobova, Sudhanshu Chakraborty, Xuan Zhu, Ruvie Martin, Sarah Whelan, Sharonjeet Kaur, Luminita Pricop, Daniel J Lovell, Alberto Martini, Nicolino Ruperto Arthritis Rheumatol. 2023; 75 (suppl 9). 2023
Predictors of Clinical Response to Abatacept in Children with Polyarticular Juvenile Idiopathic Arthritis Nicolino Ruperto, Hermine Brunner, Alberto Berman, Francisco Avila Zapata, Gerd Horneff, Linda Wagner-Weiner, Alexandre Belot, Ruben Burgos-Vargas, Maria Luz Gamir, Claudia Goldenstein-Schainberg, Maria Teresa Terreri, Margarita Askelson, Robert Wong, Alberto Martini, Daniel J Lovell. Annals of the Rheumatic Diseases 2022;81:422-423. 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis: Results from a Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA) Nicolino Ruperto, Elena Chertok, Joke Dehoorne, Gerd Horneff, Tilmann Kallinich, Ingrid Louw, Sandrine Compeyrot-Lacassagne, Bernard Lauwerys, Neil Martin, Katherine Marzan, William Knibbe, Ruvie Martin, Xuan Zhu, Xuan Zhu, Sarah Whelan, Luminita Pricop, Alberto Martini, Daniel Lovell and Hermine Brunner. Annals of the Rheumatic Diseases 2022;81:145-146. 2022
Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study Athimalaipet Ramanan, Pierre Quartier, Nami Okamoto, Gabriella Meszaros, Joana Araujo, Zhongkai Wang, Ran Liao, Brenda Crowe, Xin Zhang, Stuart Keller, Hermine Brunner, Nicolino Ruperto Annals of the Rheumatic Diseases 2022;81:207-208. 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study Brunner H, Chertok E, Dehoorne J, Horneff G, Kallinich T, Louw I, Alessio M, Compeyrot-Lacassagne S, Lauwerys B, Martin N, Marzan K, Knibbe W, Martin R, Zhu X, whelan s, Pricop L, Lovell D, Martini A, Ruperto N. Arthritis Rheumatol. 2022; 74 (suppl 9). 2022
Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials Brunner H, Ramanan A, Horneff G, Minden K, Calvo Penades I, Zucchetto M, Brockwell L, Gordon O, De Benedetti F. Arthritis Rheumatol. 2022; 74 (suppl 9). 2022
Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety
StudyRamanan A, Quartier Dit Maire P, Okamoto N, Meszaros G, Araujo J, Wang Z, Liao R, Crowe B, Zhang X, Decker R, Keller S, Brunner H, Ruperto N. Arthritis Rheumatol. 2022; 74 (suppl 9). 2022
The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase Kundakci B, Barber M, Clarke A, Johnson S, Brunner H, Cho J, Costedoat-Chalumeau N, Ginzler E, Hanly J, Hasan A, İnanç M, Kabani N, Legge A, Lima K, Lindoso L, Mak A, Ramsey-Goldman R, Ruiz-Irastorza G, Silva C, Tamirou F, Trindade V, Vinet E, Bruce I. Arthritis Rheumatol. 2022; 74 (suppl 9). 2022
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process Connelly K, Eades L, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, Gregory-Wong K, Al-Mossawi H, Andersen J, Aranow C, Arnaud L, Askanase A, Banerjee S, Barbey C, Brunner H, Buie J, Burke L, Cornet A, Costenbader K, Dall’Era M, Dantata K, Delev N, Eldred A, Friedman A, Furie R, Garces S, Grasela D, Guay H, Guenther O, Juarez M, Kafka S, Kalunian K, Karis E, Lahoud Y, Lindholm C, Lockman J, Lupton C, Maller J, Marion A, Marquis P, Merrill J, Morel T, Mosca M, Pincus Y, Pomponi S, Pons-Estel G, Ross Terres J, Sibley C, Silk M, Roy S, Simon L, Sorrentino A, Stach C, Stojan G, Sun Y, Tanaka Y, Thomas E, van Vollenhoven R, Vazquez Mateo C, Vital E, Werth V, Zollars E, Zuraw Q, Morand E. Arthritis Rheumatol. 2022; 74 (suppl 9). 2022
Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA) Nicolino Ruperto*, Ivan Foeldvari, Ekaterina Alexeeva, Nuray Aktay Ayaz, Inmaculada Calvo, Ozgur Kasapcopur, Vyacheslav Chasnyk, Markus Hufnagel, Zbigniew Żuber, Grant Schulert, Seza Ozen, Artem Popov, Athimalaipet Ramanan, Christiaan Scott, Betül Sözeri, Elena Zholobova, Xuan Zhu, Sarah Whelan, Luminita Pricop, Angelo Ravelli, Alberto Martini, Daniel J Lovell, Hermine Brunner Annals of the Rheumatic Diseases 80(Suppl 1):201-202 2021
S100a8/A9 and S100a12 As Potential Predictive Biomarkers Of Abatacept Response In Polyarticular Juvenile Idiopathic Arthritis Nicolino Ruperto*, Grant Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Anton, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert Wong, Daniel J Lovell, Alberto Martini, Alexei Grom, Hermine Brunner Annals of the Rheumatic Diseases 80(Suppl 1):245-246 2021
Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results From the PRCSG/PRINTO JIA Real-World Registry. Lovell D, Tzaribachev N, Ting T, Alexeeva E, Giani T, Griffin T, Bohnsack J, Zeft A, Vehe R, Tarvin S, Horneff G, Trachana M, Dominique A, Dong L, Kou T, Wong R, Martini A, Brunner H, Ruperto N. Arthritis Rheumatol. 2021; 73 (suppl 10). 2021
Long-term Safety and Efficacy of Abatacept Treatment in Patients with JIA: 5-year Results From the PRCSG/PRINTO JIA Real-World Registry. Brunner H, Lovell D, Henrickson M, Carrassco R, Minden K, Grebenkina L, Nocton J, Louw I, Wagner-Weiner L, Vega Cornejo G, Kamphuis S, Chasnyk V, Walters H, Appenzeller S, Anton J, Dominique A, Wong R, Dong L, Kou T, Martini A, Ruperto N. Arthritis Rheumatol. 2021; 73 (suppl 10) 2021
Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Efficacy and Safety Results from a Phase 3 Study. Brunner H, Foeldvari I, Alexeeva E, Ayaz N, Calvo Penads I, Kasapcopur O, Chasnyk V, Hufnagel M, Zuber Z, Schulert G, Ozen S, Popov A, Ramanan A, Scott C, Sozeri B, Zholobova E, Zhu X, Whelan S, Pricop L, Ravelli A, Martini A, Lovell D, Ruperto N. Arthritis Rheumatol. 2021; 73 (suppl 10). 2021
Three-year Effectiveness in Patients with JIA Initiating Abatacept: Results From the PRCSG/PRINTO JIA Real-World Registry. Ruperto N, Brunner H, Tzaribachev N, Orbán I, Staņēviča V, Quintero del Rio A, Quartier P, Huber A, Kietz D, Dare J, Kingsbury D, Graham T, Foeldvari I, Patel J, Dominique A, Dong L, Kou T, Wong R, Martini A, Lovell D. Arthritis Rheumatol. 2021; 73 (suppl 10). 2021
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry Lovell D, Brunner H, Tzaribachev N, Morgan E, Simonini G, Griffin T, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevicha V, Tarvin S, Trachana M, Huber A, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou T, Wong R, Martini A, Ruperto N. Arthritis Rheumatol. 2020; 72 (suppl 10) 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry Lovell D, Tzaribachev N, Morgan E, Simonini G, Griffin T, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevicha V, Tarvin S, Trachana M, Huber A, Kietz D, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou T, Wong R, Martini A, Brunner H, Ruperto N. Arthritis Rheumatol. 2020; 72 (suppl 10) 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept Ruperto N, Brunner H, Berman A, Ávila-Zapata F, Horneff G, Alessio M, Becker M, Belot A, Burgos-Vargas R, Boteanu A, Goldenstein-Schainberg C, Scheibel I, Terreri M, Zemel L, Wong R, Askelson M, Nys M, Martini A, Lovell D. Arthritis Rheumatol. 2020; 72 (suppl 10) 2020
THU0497 MAINTENANCE OF MINIMAL DISEASE ACTIVITY OR INACTIVE DISEASE STATUS AND PATIENT-REPORTED OUTCOMES IN INDIVIDUAL PAEDIATRIC PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH SUBCUTANEOUS ABATACEPT H. Brunner, N. Tzaribachev, I. Louw, I. Calvo, F. Zapata, G. Horneff, I. Foeldvari, D. Kingsbury, M. Gastanaga, C. Wouters, J. Breedt, R. Wong, M. Nys, M. Askelson, J. Zhuo, A. Martini, D. J. Lovell, N. Ruperto on behalf of PRINTO and PRCSG Annals of the Rheumatic Diseases 2020;79:485-486. 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept Ruperto N, Brunner H, Berman A, Ávila-Zapata F, Horneff G, Alessio M, Becker M, Belot A, Burgos-Vargas R, Boteanu A, Goldenstein-Schainberg C, Scheibel I, Terreri M, Zemel L, Wong R, Askelson M, Nys M, Martini A, Lovell D Arthritis Rheumatol. 2020; 72 (suppl 10). 2020
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry Lovell D, Brunner H, Tzaribachev N, Morgan E, Simonini G, Griffin T, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevicha V, Tarvin S, Trachana M, Huber A, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou T, Wong R, Martini A, Ruperto N Arthritis Rheumatol. 2020; 72 (suppl 10). 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry Lovell D, Tzaribachev N, Morgan E, Simonini G, Griffin T, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevicha V, Tarvin S, Trachana M, Huber A, Kietz D, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou T, Wong R, Martini A, Brunner H, Ruperto N Arthritis Rheumatol. 2020; 72 (suppl 10) 2020
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials Ruperto N, Lovell D, Bohnsack J, Breedt J, Fischbach M, Lutz T, Minden K, Miraval T, Ally M, Rubio-Pérez N, Gervais E, van Zyl R, Wong R, Nys M, Martini A, Brunner H. Arthritis Rheumatol. 2019; 71 (suppl 10) 2019
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study Brunner H, Synoverska O, Ting T, Abud Mendoza C, Spindler A, Vyzhga Y, Marzan K, Keltsev V, Tirosh I, Imundo L, Jerath R, Kingsbury D, Sozeri B, Vora S, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, V. Arthritis Rheumatol. 2019; 71 (suppl 10) 2019
USING ETHNOGRAPHY to Understand Transition in Young Adults with JIA. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018. T. Simon, M. Bradley, D. Lovell, B. Shakley, C. Zhang, L. Clark, N. Ruperto, D. McDonald, and H. I. Brunner. Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. 2018
Antibody Responses to Diptheria/Tetanus Vaccine in Paediatric Patients with Polyarticular-course Juvenile Idiopathic Arthritis Receiving Subcutaneous Abatacept. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018. N. Ruperto, H. I. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, I. Foeldvari, V. Keltsev, M. E. P. Gastanaga, C. Wouters, R. Joos, B. Lauwerys, K. Minden, J. C. Breedt, X. Li, M. Nys, R. Wong, D. J. Lovell and A. Martini. Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. 2018
The Safety Profile of Adalimumab Across Geographic Regions and Dosing Administrations Among Patients With Juvenile Idiopathic Arthritis Enrolled in the STRIVE Registry. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018. N. Ruperto, H. I. Brunner, K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, D. J. Kingsbury, K. Marzan, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Trachana-Pilavaki, M. Bereswill, H. Kupper, A. Martini, and D. Lovell. Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. 2018
Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months by Juvenile Idiopathic Arthritis Disease Category. N. Ruperto, H. I. Brunner, G. Vega-Cornejo, A. Berman, R. J. Cuttica, F. Ávila-Zapata, M. Henrickson, D. J. Kingsbury, J. F. Bohnsack, T. Lutz, N. E. Rubio-Perez, V. Gerloni, X. Li, M. Nys, R. Wong, A. Martini and D. J. Lovell. Arthritis Rheumatol., 70 (Suppl 10), 2018. 2018
THU0549 Absence of association between drug exposure and infection in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic dmards treated with sc and iv abatacept N. Ruperto, H. Brunner, N. Tzaribachev, I. Louw, I. Calvo, G. Horneff, M. Henrickson, M. Rama, M. Fischbach, T. Miraval, M. Ally, X. Li, R. Wong, M. Nys, B. Murthy, K. Lin, J. Passarell, A. Martini and D. Lovell. Annals of the Rheumatic Diseases, 77 477-477 (Suppl 2), 2018. 2018
Longitudinal Effectiveness of Abatacept in Juvenile Idiopathic Arthritis: Results From an Ongoing JIA Registry. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018. N. Ruperto, D. J. Lovell, N. Tzaribachev, A. Zeft, R. Cimaz, V. Stanevica, G. Horneff, J. Bohnsack, T. A. Griffin, R. Carrasco, M. Trachana, J. A. Dare, I. Foeldvari, R. K. Vehe, T. A. Simon, A. Martini and H. I. Brunner. Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. 2018
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry H. I. Brunner, N. Ruperto, K. Nanda, M. Toth, I. Foeldvari, J. F. Bohnsack, D. Milojevic, D. J. Kingsbury, K. A. Marzan, E. Chalom, G. Horneff, R. M. Kuester, J. A. Dare, M. Trachana, M. Bereswill, H. Kupper, D. Lovell and A. Martini. Arthritis Rheumatol., 70 (Suppl 10), 2018. 2018
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis. H. I. Brunner, N. Ruperto, D .J. Lovell, G.Horneff, M. Gámir-Gámir, M. Hufnagel,J, Hsu, M. Bao, W. Douglass, N. L. Mallalieu, C. Wells, C. M. Mela, F. De Benedetti. Arthritis Rheumatol., 70 (Suppl 10), 2018. 2018
Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis. H. I. Brunner, N. Ruperto, A. Martini, A. V. Ramanan, R. J. Cuttica, J. E. Weiss, M. Henrickson, H. Schmeling, J. Anton, K. Minden, G.Horneff, M. Gámir-Gámir, M. Hufnagel, W. Douglass, C. Wells, S. Wimalasundera, N. L. Mallalieu, D .J. Lovell and F. De Benedetti. Arthritis Rheumatol., 70 (Suppl 10), 2018. 2018
OP0103 Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis H. Brunner, N. Ruperto, D. Lovell, I. Calvo-Penedes, G. Horneff, M. Gamir Gamir, M. Hufnagel, J. Hsu, M. Bao, W. Douglass, N. Mallalieu, C. Wells, C. Mela and F. De Benedetti. Annals of the Rheumatic Diseases, 77 102-102 (Suppl 2), 2018. 2018
Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018. F. Benedetti, N. Ruperto, D. Lovell, G. Horneff, M. Gámir Gámir, M. Hufnagel, J. Hsu, M. Bao, W. Douglass, N. Mallalieu, C. Wells, C. Mela, H. I. Brunner, and PRINTO and PRCSG Investigators. Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. 2018
New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis. E. Morgan, A. Consolaro, J. Munro, J. Horonjeff, B. M. Feldman, H. Clairman, C. O. Bingham III, A. Alongi, V. Strand, M. van Rossum, R. Veselý, H. I. Brunner, D Horton, D. J. Lovell, S. Ringold, N. Ruperto, S. Schrandt, N. J. Shiff, K.Toupin-April and B.Shea. Arthritis Rheumatol., 70 (Suppl 10), 2018. 2018
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years. D. J. Lovell, N. Ruperto, A. Reiff, L. Jung, K. Jarosova, R. Mouy, I. Koné-Paut, O.Y. Jones, V. Vargova, C. Wouters, I. Galindo, C. Mak, H. I. Brunner and A. Martini. Arthritis Rheumatol., 70 (Suppl 10), 2018. 2018
OP0058 Improvement in patient-reported outcomes in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs treated with sc abatacept N. Ruperto, H. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, J. Anton, D. Viola, I. Foeldvari, V. Keltsev, D. Kingsbury, C. Wouters, B. Lauwerys, E. Alemao, R. Wong, M. Nys, S. Banerjee, A. Martini and D. Lovell. Annals of the Rheumatic Diseases, 76 75-75 (Suppl 2), 2017. 2017
THU0525 Safety of adalimumab ± methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (PJIA): strive registry N. Ruperto, H. Brunner, K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, C. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Bereswill, J. Kalabic, H. Kupper, A. Martini and D. Lovell. Annals of the Rheumatic Diseases, 76 405-405 (Suppl 2), 2017. 2017
Subcutaneous Abatacept in Patients Aged 2-17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years H. I. Brunner, N. Ruperto, Vega-Cornejo, A. Berman, I. Calvo, R. Cuttica, F. Ãvila-Zapata, M. Henrickson, D. Kingsbury, D. Viola, V. Keltsev, K. Minden, J. F. Bohnsack, X. Li, M. Nys, R. Wong, S. Banerjee, D. J. Lovell and A. Martini. Arthritis Rheumatol., 69 (suppl 10), 2017. 2017
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study H Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, R Schneider, I Kone-Paut, KN Schikler, K Marzan, N Wulffraat, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, A Speziale, K Lheritier, E Vritzali, A Martini and D. Lovell. Arthritis Rheumatol., 69 (suppl 4). (), 2017. 2017
Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry H Brunner, N Ruperto, K Nanda, M Toth, I Foeldvari, JF Bohnsack, D Milojevic, CE Rabinovich, D Kingsbury, K Marzan, P Quartier, K Minden, E Chalom, G Horneff, RM Kuester, JA Dare, M Bereswill, J Kalabic, H Kupper, DJ Lovell and A. Martini. Arthritis Rheumatol., 69 (suppl 4) (), 2017. 2017
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis H Brunner, N Ruperto, A Martini, A Ramanan, R Cuttica, JE Weiss, M Henrickson, H Schmeling, J Anton, K Minden, J Hsu, K Bharucha, S Wimalasundera, AK Kadva, R Upmanyu, NL Mallalieu, D Lovell and F. De Benedetti. Arthritis Rheumatol., 69 (suppl 4) (), 2017. 2017
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry D. J. Lovell, N. Ruperto, N. Tzaribachev, A. Zeft, R. Cimaz, V. Stanevica, G. Horneff, J. F. Bohnsack, T. A. Griffin, R. Carrasco, M. Trachana, J. A. Dare, I. Foeldvari, R. K. Vehe, T. Simon, H. I. Brunner and A. Martini. Arthritis Rheumatol., 69 (suppl 10), 2017. 2017
Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial. N. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, E. Alexeeva, R. Schneider, I. Kone-Paut, K. Schikler, K. Marzan, N. Wulffraat, S. Padeh, V. Chasnyk, C. Wouters, J. B. Kuemmerle-Deschner, T. Kallinich, B. Lauwerys, E. Haddad, E. Nasonov, M. Trachana, O. Vougiouka, K. Leon, A. Speziale, K. Lheritier, A. Martini, D. Lovell on behalf of PRINTO/PRCSG Annals of the Rheumatic Diseases, 75 265-266 (Suppl 2), 2016. 2016
Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial. N. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, E. Alexeeva, I. Kone-Paut, K. Marzan, N. Wulffraat, R. Schneider, S. Padeh, V. Chasnyk, C. Wouters, J. B. Kuemmerle-Deschner, T. Kallinich, B. Lauwerys, E. Haddad, E. Nasonov, M. Trachana, O. Vougiouka, K. Leon, A. Speziale, K. Lheritier, A. Martini D. Lovell Annals of the Rheumatic Diseases, 75 401-402 (Suppl 2), 2016. 2016
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Paediatric Patients from Two To Less than Eighteen Years of Age with Juvenile Idiopathic Arthritis. N. Ruperto, H. I. Brunner, A. Hazra, R. Wang, C. Mebus, C. Alvey, M. Lamba, S. Krishnaswami, U. Conte, M. Wang, N. Tzaribachev, I. Foeldvari, G. Horneff, D. Kingsbury, E. Koskova, E. Smolewska, R. K. Vehe, Z. Zuber, A. Martini D. Lovell Annals of the Rheumatic Diseases, 75 1202-1203 (Suppl 2), 2016. 2016
THU0216 Safety and Effectiveness of Adalimumabmethotrexate for The Treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA): Strive Registry N. Ruperto, D. Lovell, C. Wallace, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, E. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Heinrich, H. Kupper, J. Kalabic, A. Martini and H. Brunner. Annals of the Rheumatic Diseases, 75 266-266 (Suppl 2), 2016. 2016
Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response To Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety. N. Ruperto, D. J. Lovell, N. Tzaribachev, G. Vega-Cornejo, I. Louw, A. Berman, I. Calvo, R. Cuttica, G. Horneff, F. Avila-Zapata, J. Anton, D. Viola, I. Foeldvari, V. Keltsev, D. Kingsbury, X. Li, M. Nys, R. Wong, S. Banerjee, A. Martini H. I. Brunner Annals of the Rheumatic Diseases, 75 138 (Suppl 2), 2016. 2016
Safety and Effectiveness of Adalimumabmethotrexate for The Treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA): Strive Registry. N. Ruperto, D. J. Lovell, C. Wallace, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, E. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. M. Kuester, J. Dare, M. Heinrich, H. Kupper, J. Kalabic, A. Martini, H. I. Brunner, on behalf of PRINTO PRCSG Annals of the Rheumatic Diseases, 75 266 (Suppl 2), 2016. 2016
Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis I Foeldvari, N Ruperto, DJ Lovell, G Horneff, HI Huppertz, P Quartier, G Simonini, M Bereswill, J Kalabic, A Martini and HI. Brunner. Arthritis Rheumatol., 68 (suppl 10) (), 2016. 2016
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results HI Brunner, N Ruperto, V Keltsev, E Alexeeva, C Abud-Mendoza, H Schmeling, MDR Maldonado-Velázquez, N Rubio-Pérez, M Stanislav, V Chasnyk, D Brown, M Henrickson, D Kingsbury, CE Rabinovich, A Zeft, E Silverman, M Wang, P Charlton, R Lledo-Garcia, L Shaughnessy, DJ Lovell and A Martini. Arthritis Rheumatol., 68 (suppl 10) (), 2016. 2016
Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study HI Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, I Koné-Paut, K Marzan, N Wulffraat, R Schneider, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, E Vritzali, K Lheritier, A Martini and DJ. Lovell. Arthritis Rheumatol., 68 (suppl 10) (), 2016. 2016
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study H Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, R Schneider, I Kone-Paut, KN Schikler, K Marzan, N Wulffraat, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, A Speziale, K Lheritier, E Vritzali, A Martini and D. Lovell. Arthritis Rheumatol., 69 (suppl 4) (), . 2016
O43 5-Year Data from Tender, a Phase III Clinical Trial: Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis E. Baildam, F. De Benedetti, N. Ruperto, H. Brunner, C. Keane, C. Wells, J. Wang, I. Calvo, R. Cuttica, A. Ravelli, R. Schneider, D. Eleftheriou, C. Wouters, R. Xavier, L. Zemel, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Joos, A. Grom, N. Wulffraat, Z. Zuber, F. Zulian, A. Martini and D. Lovell. Rheumatology, 55 i56 (suppl_1), 2016. 2016
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety D Lovell, N Ruperto, N Tzaribachev, G Vega-Cornejo, I Louw, A Berman, I Calvo, R Cuttica, G Horneff, F Avila-Zapata, J Anton, R Cimaz, E Solau-Gervais, R Joos, G Espada, X Li, M Nys, R Wong, S Banerjee, HI Brunner and A. Martini. Arthritis Rheumatol., 68 (suppl 10) (), 2016. 2016
Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics. Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Tamas Constantin, Yackov Berkun, Inmaculada Calvo-Penedes, Mueferet Erguven, Laurence Goffin, Michael Hofer, Tilmann Kallinich et al. Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study. Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Tamas Constantin, Ekaterina Alexeeva, Isabelle Kone-Paut, Katherine Marzan, Nico Wulffraat, Rayfel Schneider, Shai Padeh et al. Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis. Hermine I. Brunner, Nicolino Ruperto, Nikolay Tzaribachev, Zbigniew Zuber, Elena Koskova, Ivan Foeldvari, Eizbieta Smolewska, Gerd Horneff, Charles Mebus, Umberto Conte et al. Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis. Daniel Lovell, Nicolino Ruperto, Daniel J. Kingsbury, Ruben Burgos-Vargas, Tomoyuki Imagawa, G. Horneff, Pierre Quartier, Steven Goodman, Andreas Reiff, Edward H. Giannini et al. Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis. Daniel Lovell, Nicolino Ruperto, Andreas Reiff, Lawrence Jung, Katerina Jarosova, Pierre Quartier, Christy Sandborg, John F. Bohnsack, Dirk Elewaut, Ivan Foeldvari et al. Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry. Daniel J. Lovell, N. Ruperto, S. Spalding, J. A. Dare, R. Cimaz, V. Stanevica, R. K. Vehe, N. Tzaribachev, G. Horneff, M. Trachana et al. Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab. Daniel J. Kingsbury, Pierre Quartier, G. Horneff, Kirsten Minden, Mary Toth, Nupun A. Varothai, Anabela Cardoso Jasmina Kalabic Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program. Alexei A. Grom, Hermine I. Brunner, Nicolino Ruperto, Alberto Martini, Daniel Lovell, Virginia Pascual, Karine Lheritier, Karolynn Leon, Ken Abrams Norman Ilowite Arthritis Rheumatol., 67 (Suppl 10), 2015. 2015
A Pharmacometric-Based Analysis Indicated No Relationship Between Occurrence of Safety Events and Canakinumab Exposure In Systemic Juvenile Idiopathic Arthritis Patients. T. Dumortier, N. Ruperto, H. I. Brunner O. Luttringer Ann Rheum Dis, 73(Suppl2) (), 2014. 2014
Efficacy of canakinumab in biologic-naive versus previously biologic-exposed SJIA patients: a 12-week pooled post-hoc analysis. P. Quartier, A. Grom, N. Ruperto, H. I. Brunner, K. Schikler, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, K. Marzan, C. Gaillez, K. Lheritier, K. Abrams, A. Martini D. J. Lovell Pediatric Rheumatology, 12 P66 (Suppl 1), 2014. 2014
A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. Arthritis & Rheumatology. P. Lu, J. Hsu, C. Keane, S. Fettner, J. Wang, N. Ruperto, O. Harari, H. Brunner F. D. Benedetti Arthritis & Rheumatology, 66 S222–S223 (), 2014. 2014
High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy in juvenile idiopathic arthritis. Nirit Mor-Vaknin, Miguel Rivas, Maureen Legendre, Y. Yuanfang, Anne Johnson, Bin Huang, Yuki Kimura, Lili Zhao, Steve Spalding, Paula Morris, Beth Gottlieb, Karen Onel, Judyann Olson, Barbara Edelheit, Michael Shishov, Larry Jung, Elaine Cassidy, Sampath Prahalad, Murray Passo, Timothy Beukelman, Jay Mehta, Kara Schmidt, Ed Giannini, Daniel Lovell David Markovitz Pediatric Rheumatology, 12 P8 (Suppl 1), 2014. 2014
A44: High Levels of DEK Autoantibodies May Predict Early Flare Following Cessation of Anti-TNF Therapy. Nirit Mor-Vaknin, Miguel Rivas, Maureen Legendre, Cynthia Yuanfan Ye, Anne Johnson, Bin Huang, Lili Zhao, Yuki Kimura, Steven J. Spalding, Paula Morris, Beth Gottlieb, Karen Onel, Judyann C. Olson, Barbara Edelheit, Michael Shishov, Lawrence K. Jung, Elaine Cassidy, Sampath Prahalad, Murray H. Passo, Timothy Beukelman, Jay Mehta, Kara M. Schmidt, Edward H. Giannini, Daniel J. Lovell David Markovitz Arthritis & Rheumatology, 66 S65-S66 (), 2014. 2014
Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial. Nicola Ruperto, Daniel Lovell, Pierre Quartier, Angelo Ravelli, Mahinda Karunaratne, Jasmina Kalabic, Anabela Cardoso, Alberto Martini Gerd Horneff Pediatric Rheumatology, 12 P9 (Suppl 1), 2014. 2014
Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data. N. Ruperto, H. I. Brunner, I. Kone-Paut, B. Magnusson, S. Ozen, F. Sztajnbok, J. Anton, J. Barash, F. Corona, K. Lheritier, C. Gaillez, A. Martini D. Lovell Pediatric Rheumatology, 12 O12 (Suppl 1), 2014. 2014
Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients. N. M. Wulffraat, N. Ruperto, H. I. Brunner, S. Oliveira, Y. Uziel, K. Nistala, R. Cimaz, M. A. Ferrandiz, B. Flato, M. L. Gamir, I. Koné-Paut, C. Gaillez, K. Lheritier, K. Abrams, A. Martini D. J. Lovell Ann Rheum Dis, 73(Suppl2) (), 2014. 2014
Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients. N. M. Wulffraat, N. Ruperto, H. I. Brunner, S. Oliveira, Y. Uziel, K. Nistala, R. Cimaz, M. A. Ferrandiz, B. Flato, M. Gamir, I. Kone-Paut, C. Gaillez, K. Lheritier, K. Abrams, A. Martini D. Lovell Pediatric Rheumatology, 12 P68 (Suppl 1), 2014. 2014
An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis.. Hermine I. Brunner, Nicola Ruperto, Isabelle Kone-Paut, Bo Magnusson, Seza Ozen, Flavio Sztajnbok, Jordi Anton, Judith Barash, Reinhard Berner, Fabrizia Corona et al. Arthritis Rheumatol., 66 S413-S413 (), 2014. 2014
A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results. Hermine Brunner, Nicolino Ruperto, N. Tzaribachev, Gerd Horneff, Carine Wouters, V. Panaviene, Vyacheslav Chasnyk, Carlos Abud-Mendoza, Ruben Cuttica, Andreas Reiff et al. Arthritis & Rheumatology, 66 S191-S192 (S3), 2014. 2014
A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study . H. Mirjafari, N. Ruperto, H. I. Brunner, Z. Zuber, F. Zulian, M. R. Maldonado-Velázquez, E. Mantzourani, K. Murray, J. Roth, J. Rovensky, O. Vougiouka, J. Wang, O. Harari, D. Lovell, A. Martini F. De Benedetti Arthritis & Rheumatology, 66 S80-81 (), 2014. 2014
A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. H. Brunner, N. Ruperto, Z. Zuber, R. J. Cuttica, R. Xavier, I. Calvo, N. Rubio, E. Alekseeva, V. Chasnyk, J. Chavez, G. Horneff, V. Opoka-Winiarska, P. Quartier, A. Spindler, C. Keane, K. N. Bharucha, J. Wang, D. J. Lovell, A. Martini F. De Benedetti Arthritis & Rheumatology, 66 S5-6 (), 2014. 2014
Long-term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis. G. Horneff, N. Ruperto, C. Wallace, M. Bereswill, A. Cardoso, J. Kalabic, H. Kupper H. Brunner Ann Rheum Dis, 73(Suppl2) (), 2014. 2014
Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Francesca Minoia, Sergio Davi, Francesca Bovis, Angela Pistorio, Maurizio Arico, Tadej Avcin, Ed Behrens, Fabrizio De Benedetti, Lisa Filipovich, Alexei Grom, Jan-Inge Henter, AnnaCarin Horne, Norman Ilowite, Michael Jordan, Raju Khubchandani, Toshiyuki Kitoh, Kai Lehmberg, Dan Lovell, Paivi Miettunen, Kim Nichols, Jana Pachlopnik, Seza Ozen, Athimalaipet Ramanan, Ricardo Russo, Rayfel Schneider, Gary Sterba, Carol Wallace, Carine Wouters, Nico Wulffraat, Yosef Uziel, Nicola Ruperto, Alberto Martini, Randy Cron Angelo Ravelli Pediatric Rheumatology, 12 O1 (Suppl 1), 2014. 2014
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from the TENDER trial. Fabrizio De Benedetti, Hermine Brunner, Nicolino Ruperto, Rayfel Schneider, Ricardo Xavier, Roger Allen, Diane Brown, Jeffrey Chaitow, Manuela Pardeo, Graciela Espada, Valeria Gerloni, Barry Myones, James Frane, Jianmei Wang, Terri H. Lipman, Kamal N. Bharucha, Alberto Martini, Daniel Lovell, the Paediatric Rheumatology International Trials Organisation (PRINTO) Pediatric Rheumatology Collaborative Study Group (PRCSG) Arthritis & Rheumatology, n/a-n/a (), 2014. 2014
Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study. F. De Benedetti, N. Ruperto, H. Brunner, A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. K. Kadva, J. Wang, A. Martini D. Lovell Pediatric Rheumatology, 12 O13 (Suppl 1), 2014. 2014
A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. F. De Benedetti, N. Ruperto, H. Brunner, A. A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. K. Kadva, J. Wang, A. Martini D. J. Lovell Arthritis & Rheumatology, 66 S8-9 (Suppl 11), 2014. 2014
A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis . F. De Benedetti, N. Ruperto, E. Baildam, R. Burgos-Vargas, G. Horneff, H. I. Huppertz, K. Minden, B. L. Myones, K. Onel, J. Wang, K. N. Bharucha, D. J. Lovell, A. Martini H. Brunner Arthritis & Rheumatology, 66 S23-24 (), 2014. 2014
Understanding the biology and use of TNF therapy in jia-clinical outcomes. Daniel Lovell, Anne Johnson, Yuki Kimura, Steve Spalding, Paula Morris, Beth Gottlieb, Karen Onel, Judyann Olson, Barbara Edelheit, Michael Shisov, Lawrence Jung, Elaine Cassidy, Sampath Prahalad, Murray Passo, Tim Beukelman, Jay Mehta, Kara Schmidt, Dirk Foell, Claas Hinze, Bin Huang Edward Giannini Pediatric Rheumatology, 12 P137 (Suppl 1), 2014. 2014
A20: Understanding the Use and Biology of TNF Therapy in JIA-Clinical Outcomes. Daniel J. Lovell, Anne Johnson, Yuki Kimura, Steven J. Spalding, Paula W. Morris, Beth S. Gottlieb, Karen Onel, Judyann C. Olson, Barbara Edelheit, Michael Shishov, Lawrence Jung, Elaine Cassidy, Sampath Prahalad, Murray H. Passo, Timothy Beukelman, Jay Mehta, Kara M. Schmidt, Dirk Foell, Bin Huang Edward H. Giannini Arthritis & Rheumatology, 66 S31-S32 (), 2014. 2014
A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment. D. J. Lovell, N. Ruperto, R. Mouy, E. Paz, N. Rubio-Perez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. S. Magalhaes, J. Chavez-Corrales, C. Huemer, A. J. Kivitz, F. J. Blanco, I. Foeldvari, M. Hofer, H.-I. Huppertz, C. Deslandre, K. Minden, A. J. Block, E. H. Giannini A. Martini Arthritis & Rheumatology, 66 S218-219 (), 2014. 2014
A12: The Role of Serum S100A12 Protein Levels in Disease Flare After Withdrawal of Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis. Claas Hinze, Dirk Foell, Anne Johnson, Yukiko Kimura, Steven J. Spalding, Paula W. Morris, Beth Gottlieb, Karen Onel, Judyann C. Olson, Barbara Edelheit, Michael Shishov, Lawrence Jung, Elaine Cassidy, Sampath Prahalad, Murray H. Passo, Timothy Beukelman, Jay Mehta, Kara M. Schmidt, Edward H. Giannini Daniel J. Lovell Arthritis & Rheumatology, 66 S19-S20 (), 2014. 2014
Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Alessandro Consolaro, Francesca Bovis, Ekaterina Alexeeva, Violeta Panaviene, Jordi Anton, Susan Nielsen, Gordana Susic, Maria Trachana, Troels Herlin, Nico Wulffraat, Pavla Dolezalova, Yosef Uziel, Nahid Shafaie, Ingrida Rumba-Rozenfelde, Valda Stanevicha, Nicolino Ruperto, Daniel Lovell, Angelo Ravelli, Alberto Martini PRINTO Pediatric Rheumatology, 12 P176 (Suppl 1), 2014. 2014
A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. A. Ravelli, N. Ruperto, S. Pederzoli, R. Burgos-Vargas, K. Kobusinska, H. Schmeling, F. Sztajnbok, F. Weller-Heinemann, E. Zholobova, F. Zulian, R. Allen, J. Chaitow, C. Keane, C. Wells, A. Martini, D. J. Lovell F. De Benedetti Arthritis & Rheumatology, 66 S17–S18 (), 2014. 2014
Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset. A. Ravelli, H. I. Brunner, N. Ruperto, P. Quartier, A. Consolaro, N. Wulffraat, K. Lheritier, C. Gaillez, A. Martini D. J. Lovell Pediatric Rheumatology, 12 P69 (Suppl 1), 2014. 2014
Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA — an analysis of 12-week pooled data. A. Ravelli, H. I. Brunner, N. Ruperto, P. Quartier, A. Consolaro, N. Wulffraat, K. Lheritier, C. Gaillez, A. Martini D. J. Lovell Pediatric Rheumatology, 12 P63 (Suppl 1), 2014. 2014
Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA-an analysis of 12-week pooled data. A. Ravelli, H. I. Brunner, N. Ruperto, P. Quartier, A. Consolaro, N. Wulffraat, K. Lheritier, C. Gaillez, A. Martini D. J. Lovell Pediatric Rheumatology, 12 P63 (Suppl 1), 2014. 2014
Canakinumab in Biologic-naive Versus Previously Biologic-Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis. A. Grom, P. Quartier, N. Ruperto, H. I. Brunner, K. Schikler, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, K. Marzan et al. Arthritis Rheumatol., 66 S999-S999 (), 2014. 2014
Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy. A. Brachat, A. Grom, N. Wulffraat, H. Brunner, P. Quartier, R. Brik, L. McCann, H. Ozdogan, L. Rutkowska-Sak, R. Schneider, V. Gerloni, L. Harel, M. Terreri, K. Houghton, R. Joos, D. Kingsbury, J. Lopez-Benitez, S. Bek, M. Schumacher, M. Valentin, H. Gram, K. Abrams, A. Martini, N. Ruperto, D. Lovell N. Nirmala Ann Rheum Dis, 73(Suppl2) (), 2014. 2014
Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome. A. A. Grom, H. I. Brunner, N. Ruperto, A. Martini, D. Lovell, V. Pascual, K. Lheritier, K. Abrams N. Ilowite Ann Rheum Dis, 73(Suppl2) (), 2014. 2014
Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis. Y. Xiong, W. Wang, V. Ebling, H. Sun, O. Luttringer, K. . Abrams, N. Ruperto H. Brunner Pediatric Rheumatology, 11(Suppl 2) P181 (), 2013. 2013
Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in polyarticular juvenile idiopathic arthritis. Scott Fettner, Peng Lu, Joy Hsu, Caroline Keane, Jianmei Wang, Nicolino Ruperto, Fabrizio De Benedetti Hermine Brunner Pharmacotherapy, 33(10) e234 (), 2013. 2013
Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in polyarticular juvenile idiopathic arthritis. Scott Fettner, Peng Lu, Joy Hsu, Caroline Keane, Jianmei Wang, Nicolino Ruperto, Fabrizio De Benedetti Hermine Brunner Pharmacotherapy, 33(10) e182-e299 (), 2013. 2013
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program. Rayfel Schneider, Hermine I. Brunner, Nicolino Ruperto, Nico Wulffraat, Pierre Quartier, Riva Brik, Liza McCann, Helen E. Foster, Michael Frosch, Valeria Gerloni, Liora Harel, Claudio Len, Kristin Houghton, Rik Joos, Ken Abrams, Karine Lheritier, Sophia Kessabi, Alberto Martini Daniel J. Lovell Arthritis & Rheumatism, 65(Suppl 10) S111 (), 2013. 2013
Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients . P. Quartier, N. Ruperto, N. Wulffrat, H. Brunner, R. Brik, L. McCann, H. Foster, M. Frosch, V. Gerloni, L. Harel, C. Len, K. Houghton, R. Joos, K. Abrams, K. Lheritier, S. Kessabi, A. Martini D. Lovell Pediatric Rheumatology, 11(Suppl 2) P170 (), 2013. 2013
Canakinumab Improves Health-Related Quality of Life (HRQOL) and Daily Functioning in Systemic Juvinile Idiopathic Arthritis (SJIA) Patients. P. Quartier, N. Ruperto, N. Wulffrat, H. Brunner, R. Brik, L. McCann, H. Foster, M. Frosch, V. Gerloni, L. Harel, C. Len, K. Houghton, R. Joos, D. Kim, K. Abrams, K. Lheritier, J. Ricci, A. Martini D. Lovell Ann Rheum Dis, 72(Suppl 3) 325 (), 2013. 2013
Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis. P. Quartier, H. Brunner, T. Constantin, S. Padeh, I. Calvo, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, S. Oliveira, Y. Uziel, S. Viola, K. Nistala, C. Wouters, K. Lheritier, J. Hruska, K. Abrams, A. Martini, N. Ruperto D. Lovell Pediatric Rheumatology, 11(Suppl 2) P169 (), 2013. 2013
Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients. P. Lu, J. Hsu, C. Keane, S. Fettner, J. Wang, N. Ruperto, O. Harari, H. I. Brunner F. De Benedetti Pediatric Rheumatology, 11(Suppl 2) P171 (), 2013. 2013
Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy. Nanguneri Nirmala, Nico Wulffraat, Hermine Brunner, Pierre Quartier, Riva Brik, Liza McCann, Huri Ozdogan, Lidia Rutkowska-Sak, Rayfel Schneider, Valeria Gerloni, Liora Harel, Maria Terreri, Kristin Houghton, Rik Joos, Daniel Kingsbury, Jorge M. Lopez-Benitez, Arndt Brachat, Stephan Bek, Martin Schumacher, Marie-Anne Valentin, Hermann Gram, Ken Abrams, Alberto Martini, Nicolino Ruperto Daniel J. Lovell Arthritis & Rheumatism, 65(Suppl 10) S716 (), 2013. 2013
Baseline characteristics of patients with active systemic JIA successfully discontinuing corticosteroid while receiving canakinumab: secondary analysis from a pivotal Phase 3 trial. N. Ruperto, H. Brunner, T. Constantin, N. Wulffraat, G. Horneff, J. Anton, R. Berner, F. Corona, R. Cuttica, M. Desjonqueres, M. Fischbach, M. Alessio, A. Chieng, W. Emminger, E. Haddad, K. Lheritier, K. Abrams, J. Hruska, D. Kim, A. Martini D. Lovell Ann Rheum Dis, 72(Suppl 3) 97 (), 2013. 2013
Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients. N. Ruperto, D. J. Lovell, K. Jarosova, D. Nemcova, V. Vargová, H. Michels, E. C. Chalom, N. Ilowite, C. Wouters, H. I. Brunner, K. K. Kracht, H. Kupper, E. Giannini, A. Martini N. Mozaffarian Pediatric Rheumatology, 11(Suppl 2) O4 (), 2013. 2013
Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy. N. Nirmala, N. Wulffraat, H. Brunner, P. Quartier, R. Brik, L. Mccann, H. Ozdogan, L. Rutkowska-Sak, R. Schneider, V. Gerloni, L. Harel, M. Terreri, K. Houghton, R. Joos, D. Kingsbury, J. Lopez-Benitez, S. Radominski, A. Brachat, S. Bek, M. Schumacher, M. Valentin, H. Gram, K. Abrams, A. Martini, N. Ruperto D. Lovell Pediatric Rheumatology, 11(Suppl 2) P168 (), 2013. 2013
Efficacy of Biologic Treatments in Juvenile Idiopathic Arthritis with a Polyarticular Course: and Indirect Comparison. L. Sawyer, A. Diamantopoulos, H. Brunner, F. De Benedetti, N. Ruperto, F. Dejonckheere C. Keane Ann Rheum Dis, 72(Suppl3) 740 (), 2013. 2013
Efficacy and Safety of Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis: Cherish Results at Week 40. L. Sawyer, A. Diamantopoulos, H. Brunner, F. De Benedetti, N. Ruperto, F. Dejonckheere C. Keane Rheumatology, Volume 52 suppl 1 i33-i43 (), 2013. 2013
Efficacy and Safety Of Tocilizumab In Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From Cherish. Hermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Rubén J. Cuttica, Ricardo Xavier, Inmaculada Calvo, Nadina Rubio, Ekaterina Alekseeva, Vyacheslav Chasnyk, Jose Chavez, Gerd Horneff, Violetta Opoka-Winiarska, Pierre Quartier, Alberto Spindler, Caroline Keane, Kamal N. Bharucha, Jianmei Wang, Daniel J. Lovell, Alberto Martini Fabrizio De Benedetti Arthritis & Rheumatism, 65(Suppl 10) S335 (), 2013. 2013
Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study. H. Mirjafari, N. Ruperto, H. I. Brunner, Z. Zuber, F. Zulian, M. R. Maldonado-Velázquez, E. Mantzourani, K. Murray, J. Roth, J. Rovensky, O. Vougiouka, J. Wang, O. Harari, D. Lovell, A. Martini F. De Benedetti Pediatric Rheumatology, 11(Suppl 2) O23 (), 2013. 2013
Canakinumab In The Treatment Of Systemic Juvenile IdiopathicArthritis: Results From a 12-Week Pooled Post-Hoc Analysis ForEfficacy. H. Brunner, P. Quartier, T. Constantin, S. Padeh, I. Calvo, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, S. Oliveira, Y. Uziel, S. Viola, K. Nistala, C. Wouters, K. Lheritier, J. Hruska, K. Abrams, A. Martini, N. Ruperto D. Lovell Arthritis & Rheumatism, 65(Suppl 10) S112 (), 2013. 2013
Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in patients with systemic juvenile idiopathicarthritis. Fabrizio De Benedetti, Hermine Brunner, Caroline Fettner, Scottand Keane, Clare Devlin Nicolino Wang, Jianmei andRuperto Pharmacotherapy, 33(10) e234 (), 2013. 2013
Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH. F. F De Benedetti, N. Ruperto, Z. Zuber, R. Cuttica, R. Xavier, I. Clavo, N. Rubio, E. Alekseeva, V. Chasnyk, J. Chavez, G. Horneff, V. Opoka-Winiarska, P. Quartier, A. Spindler, C. Keane, K. Bharucha, J. Wang, D. Lovell, A. Martini H. I. Brunner Pediatric Rheumatology, 11(Suppl 2) O15 (), 2013. 2013
Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study . F. De Benedetti, N. Ruperto, H. I. Brunner, A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. K. Kadva, J. Wang, A. Martini D. Lovell Pediatric Rheumatology, 11(Suppl 2) P151 (), 2013. 2013
Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA). F. De Benedetti, H. I. Brunner, E. Baildam, R. Burgos-Vargas, G. Horneff, H. I. Huppertz, K. Minden, B. L. Myones, K. Onel, J. Wang, K. Bharucha, D. Lovell, A. Martini N. Ruperto Pediatric Rheumatology, 11(Suppl 2) P152 (), 2013. 2013
Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial. C. Malattia, N. Ruperto, E. Palmisani, S. Pederzoli, A. Pistorio, H. I. Brunner, R. Cuttica, I. Calvo, S. M. Garay, D. Eleftheriou, C. Wouters, J. Wang, C. Devlin, D. Lovell, A. Martini, F. De Benedetti A. Ravelli Pediatric Rheumatology, 11(Suppl 2) P147 (), 2013. 2013
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis. Rachel E. Sobel, D. J. Lovell, Hermine I. Brunner, Jennifer E. Weiss, Paula W. Morris, Beth S. Gottlieb, Elizabeth C. Chalom, Lawrence K. Jung, Karen Onel, Lisa Petinoit, Donald P. Goldsmith, Staci Abramsky-Risman, James P. Young Edward H. Giannini Arthritis & Rheumatism, 64(10) S489 (), 2012. 2012
Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy. Nico Wulffraat, Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Riva Brik, Liza McCann, Huri Ozdogan, Lidia Rutkowska-Sak, Rayfel Schneider, Valeria Gerloni, Liora Harel, Maria Hilário, Kristin Houghton, Rik Joos, Daniel Kingsbury, Arndt Brachat, Stephan Bek, Martin Schumacher, Marie-Anne Valentin, N. R. Nirmala, Hermann Gram, Ken Abrams, Alberto Martini D. J. Lovell Arthritis & Rheumatism, 64(10) S328 (), 2012. 2012
Efficacy and Safety of Canakinumab in Patients with Active SystemicJuvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase 3 Trials. Hermine I. Brunner, Nicolino Ruperto, Tamas Quartier, Pierre andConstantin, Nico Wulffraat, Gerd Horneff, Liza Brik, Riva andMcCann, Huri Ozdogan, Lidia Rutkowska-Sak, Yackov Schneider, Rayfel andBerkun, Inmaculada Calvo, Muferet Erguven, Michael Goffin, Laurence andHofer, Tilmann Kallinich, Karine Lheritier, Andrea Abrams, Ken andStancati, D. J. Lovell Alberto Martini Arthritis & Rheumatism, 64(10) S326 (), 2012. 2012
Efficacy and Safety of Tocilizumab in Patients with Polyarticular JuvenileIdiopathic Arthritis: Data From a Phase 3 Trial. Hermine Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, Andrew Kenwright, Rube´n J. Cuttica, Vladimir Keltsev, Ricardo Xavier, Inmaculada Calvo Penades, Irina Nikishina, Nadina Rubio-Perez, Ekaterina Alekseeva, Vyacheslav Chasnyk, Jose Chavez, Gerd Horneff, Violetta Opoka-Winiarska, Pierre Quartier, Clovis A. Silva, Earl D. Silverman, Alberto Spindler, D. J. Lovell, Alberto Martini Fabrizio De Benedetti Arthritis & Rheumatism, 64(10) S682 (), 2012. 2012
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study. Hermine Brunner, Nicolino Ruperto, Tamás Constantin, Nico Wulffraat, Gerd Horneff, Jordi Anton, Reinhard Berner, Fabrizia Corona, Rubén J. Cuttica, Marine Desjonqueres, Michel Fischbach, Maria Alessio, Alice Chieng, Wolfgang Emminger, Elie Haddad, Karine Lheritier, Ken Abrams, Josef Hruska, Daniel J. Lovell Alberto Martini Arthritis & Rheumatism, 64(10) S113 (), 2012. 2012
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial. F. De Benedetti, N. Ruperto, G. Espada, V. Gerloni, B. Flato, G. Horneff, B. Myones, K. Onel, J. Frane, A. Kenwright, T. H. Lipman, K. N. Bharucha, A. Martini D. Lovell Arthritis & Rheumatism, 64(10) 760 (), 2012. 2012
Pharmacokinetics (PK) and Pharmacodynamics (PD) OF Tocilizumab (TCZ) in Systemic Juvenile Idiopathic Arthritis (sJIA). X. Zhang, P. N. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell EULAR (2011) European League Against Rheumatism 2011, (), 2011. 2011
Pharmacokinetics and Pharmacodynamics of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. X. Zhang, P. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell ACCP (2011) American College of Clinical Pharmacy – Annual Meeting 2011, (), 2011. 2011
Predictors for the Effectiveness of Dexamethasone Iontophoresis for the Treatment of TMJ-Involvement in JIA. R. Mina, M. Rao, S. Powell, J. Pendl, P. G. Melson H. Brunner Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. 2011
MRI Findings from the Trial of Early Aggressive Therapy (TREAT) Study. M. Thapa, S. J. Spalding, P. J. Hashkes, S. Ringold, A. S. Zeft, R. P. Sundel, R. K. Otto, E. H. Giannini, D. J. Lovell C. A. Wallace Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. 2011
Phase III Study Results on the Efficacy and Safety of Canakinumab, a Long-Acting, Fully Human Anti-Interleukin-1 Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features. Hermine Brunner, Nicolino Ruperto, Gerd Horneff, Pierre Quartier, Tamás Constantin, Berkun Yackov et al Arthritis Rheum 2011, 63 Suppl 10 2622 (), 2011. 2011
Tocilizumab Is Efficacious in Patients with Systemic Juvenile Idiopathic Arthritis Across Baseline Demographic and Disease Characteristics and Prior/Baseline Treatments: 52-Week Data From a Phase 3 Clinical Trial. Fabrizio De Benedetti, Hermine Brunner, Roger Allen, Diane Brown, Jeffrey Chaitow, Manuela Pardeo et al Arthritis Rheum 2011, 63 Suppl 10 2621 (), 2011. 2011
Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data. F. De Benedetti, H. Brunner, N. Ruperto, R. Cuttica, C. Malattia, R. Schneider, P. Woo, D. Eleftheriou, E. Baildam, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Joos, N. Wulffraat, Z. Zuber, F. Zulian, C. Wouters, R. M. Xavier, L. Zemel, S. Wright, A. Kenwright, A. Martini D. Lovell Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. 2011
Efficacy and Safety of Tocilizumab (TCZ) in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data. F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, S. Wright, A. Kenwright, D. Lovell A. Martini EULAR (2011) European League Against Rheumatism 2011, (), 2011. 2011
Efficacy and Safety of Tocilizumab (TCZ) in Patients (pts) with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data. F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, S. Wright, A. Kenwright, D. Lovell A. Martini PReS (2011) Paediatric Rheumatology European Society – 18th Congress, (), 2011. 2011
Efficacy and Safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 2-year Data From a Phase 3 Clinical Trial. F. De Benedetti, H. Brunner, N. Ruperto, A. Kenwright, C. Devlin, I. Calvo, Cuttica, Ravelli, Schneider, Eleftheriou, Wouters, Xavier, Zemel, Baildam, Burgos-Vargas, Dolezalova, Garay, Joos, Grom, Wulffraat, Zuber, Zulian, Martini Lovell ACR/ARHP (2011) American College of Rheumatology/ARHP Annual Scientific Meeting – 2011 (formerly ACR), (), 2011. 2011
Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis. Daniel J. Lovell, Nicolino Ruperto, Andreas Reiff, Lawrence K. Jung, Gloria Higgins, Isabelle Kone-Paut et al Arthritis Rheum 2011, 63 Suppl 10 265 (), 2011. 2011
Understanding the Biology and Use of Anti-TNF Agents in JIA – Interim Results. D. J. Lovell, S. P. Spalding, K. Onel, B. S. Gottlieb, H. I. Brunner, Y. Kimura, P. W. Morris, J. C. Olson, A. Johnson E. H. Giannini Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. 2011
The Effects of Early Aggressive Therapy in JIA: Results of the TREAT Study. C. A. Wallace, E. H. Giannini, S. J. Spalding, P. J. Hashkes, K. M. O’Neil, A. S. Zeft, I. S. Szer, S. M. Ringold, H. Brunner, L. E. Schanberg, R. P. Sundel, D. Milojevic, M. G. Punaro, P. Chira, B. S. Gottlieb, G. C. Higgins, N. T. Ilowite, Y. Kimura, B. Huang, D. J. Lovell Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. 2011
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis. A. Zhang, P. N. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell ASCPT (2011) American Society for Clinical Pharmacology and Therapeutics – 112th Annual Meeting, (), 2011. 2011
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. S. Visvanathan, C. Wagner, J. Marini, D. J. Lovell, A. Martini, et al , for P. R. I. N. T. O. for P. R. C. S. G. Pediatric Rheumatology, 8:24 (), 2010. 2010
Effectiveness of Dexamethasone Iontophoresis in Temporomandibular Joint (TMJ)-Arthritis in Juvenile Idiopathic Arthritis (JIA). R. Mina, P. G. Melson, S. Powell, C. H. Hinze, J. Pendl, T. B. Graham H. I. Brunner Proceeding of the American College of Rheumatology Annual Meeting, (), 2010. 2010
Effectiveness of Dexamethasone Iontophoresis in Temporomandibular Joint (TMJ)-Arthritis in Juvenile Idiopathic Arthritis (JIA). R. Mina, P. G. Melson, S. Powell, C. H. Hinze, J. Pendl, T. B. Graham H. I. Brunner Proceeding of the 17th Pediatric Rheumatology European Society Rheumatology Congress, (), 2010. 2010
Tocilizumab Is Efficacious in Patients With Systemic Juvenile Idiopathic Arthritis Across Baseline Disease Characteristics and Prior or Baseline Treatments: 12-week Data From the Phase 3 TENDER Trial. N. Ruperto, F. De Benedetti, H. Brunner, R. Allen, D. Brown, J. Chaitow, E. Cortis, G. A. Espada, B. Flato, V. Gerloni, G. Horneff, S. Wright, A. Kenwright, R. Schneider, P. Woo, A. Martini D. Lovell PReS (2010) Paediatric Rheumatology European Society – 17th Congress, (), 2010. 2010
Tocilizumab Improves Systemic and Laboratory Features of Systemic Juvenile Idiopathic Arthritis: 12-Week Data from the Phase 3 TENDER Trial. F. De Benedetti, N. Ruperto, H. Brunner, E. Baildam, R. Burgos, P. Dolezalova, S. M. Garay, J. Gracia-Consuegra, J. Joos, N. Wulffraat, Z. Zuber, F. Zulian, A. Grom, F. Schaefer, S. Wright, A. Kenwright, A. Martini D. Lovell PReS (2010) Paediatric Rheumatology European Society – 17th Congress, (), 2010. 2010
Efficacy and Safety of Tocilizumab In Patients With Systemic Juvenile Idiopathic Arthritis (sJIA): 12-Week Data From The Phase 3 TENDER Trial. F. De Benedetti, H. Brunner, N. Ruperto, S. Wright, A. Kenwright, R. Cuttica, P. Woo, R. Schneider, D. Lovell A. Martini EULAR (2010) European League Against Rheumatism 2010, (), 2010. 2010
Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-Week Data From the Phase 3 TENDER Trial. F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, S. Wright, A. Kenwright, D. Lovell A. Martini PReS (2010) Paediatric Rheumatology European Society – 17th Congress, (), 2010. 2010
Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: Efficacy Data from the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial. F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. H. Wouters, R. Xavier, L. S. Zemel, S. Wright, A. Kenwright, A. Martini D. J. Lovell Proceeding of the American College of Rheumatology Annual Meeting, (), 2010. 2010
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Data From the Phase 3 TENDER Study. A. Zhang, P. N. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell EULAR (2010) European League Against Rheumatism 2010, (), 2010. 2010
Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Pharmacokinetics (PK) and Pharmacodynamics (PD) Data from the Phase 3 TENDER Trial. A. Zhang, H. Brunner, P. N. Morcos, H. I. Huppertz, K. Minden, B. Myones, K. Onel, A. Siammopoulou, C. Silva, A. Kenwright, S. Roseti, F. De Benedetti, D. Lovell, A. Martini N. Ruperto PReS (2010) Paediatric Rheumatology European Society – 17th Congress, (), 2010. 2010
Effects of Long-Term Treatment with Etanercept on Growth in Children with Polyarticular Course or Systemic Juvenile Rheumatoid Arthritis. E. Giannini, N. Ilowite D. Lovell Ann Rheum Dis, 68(Suppl 3):308 (), 2009. 2009
Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). D. J. Lovell, E. H. Giannini, Y. Kimura et al Arthr and Rheum, 60 (10) suppl: S 768 (abst #2053) (), 2009. 2009
The Long-term Safety of Etanercept (Enbrel®) in Children with Polyarticular or Systemic Juvenile Rheumatoid Arthritis.. E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, E. C. Rabinovich, A. O. Reiff, G. C. Higgins, Y. Chon S. L. Lin Proc Am Coll Rheum Keystone Pediatric Rheumatology Symposium, (), 2008. 2008
Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis. E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. O. Reiff, G. Higgins, B. Gottlieb, Y. Chon, S. W. Baumgartner S. L. Lin Proceeding of the 15th Pediatric Rheumatology European Society Rheumatology Congress, 7.5 (), 2008. 2008
Safety and Efficacy of Over 8 Years of Continuous Etanercept (Enbrel®) Therapy in Patients With Juvenile Rheumatoid Arthritis. A. O. Reiff, D. J. Lovell, N. T. Ilowite, C. A. Wallace, Y. Chon, S. L. Lin, S. W. Baumgartner E. H. Giannini Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2008. 2008
A new multi-center registry to monitor long-term safety of non-steroidal anti-inflammatory drugs (NSAIDs) including celebrex in juvenile idiopathic arthritis (JIA). R. E. Sobel, D. J. Lovell, E. H. Giannini, N. Sheth, S. Abramsky G. Calkwell Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 193 (), 2007. 2007
Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis after abatacept withdrawal and subsequent re-introduction. N. Ruperto, E. H. Giannini, P. Quartier, N. Rubio-Perez, C. A. Silva, C. Abud, L. Sigal, A. Block, A. Martini D. J. Lovell Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 166 (), 2007. 2007
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis: Results of a double-blind withdrawal phase. N. Ruperto, E. H. Giannini, P. Quartier, N. Rubio-Perez, C. A. Silva, C. Abud, L. Sigal, A. Block, A. Martini D. J. Lovell Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 82-83 (), 2007. 2007
Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis after abatacept withdrawal and subsequent re-introduction. N. Ruperto, E. H. Giannini P. Quartier Ann Rheum Dis, 66 436 (), 2007. 2007
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing. N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, L. Jung, K. Jarasova, I. Foeldari, J. Rovensky, K. Minden, R. Vehe, G. H. Horneff, M. McIlraith, J. Medich, A. Martini E. H. Giannini Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 176-177 (), 2007. 2007
Two-year efficacy of adalimumab in children with juvenile rheumatoid arthritis (JRA): Results of a phase III trial. N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, D. Nemcova, A. M. Prieur, R. Joos, V. Gerloni, J. Bohnsack, L. Wagner-Weiner, H. I. Huppertz, N. Olson, M. McIlraith, J. Medich, A. Martini E. H. Giannini Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 84 (), 2007. 2007
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Data over two years of treatment in a phase III trial. N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, A. Martini E. H. Giannini Ann Rheum Dis, 66 185 (), 2007. 2007
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing in the open-label extension (OLE) of a phase III study. N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, A. Martini E. H. Giannini Ann Rheum Dis, 66 185 (), 2007. 2007
Clinical trial safety data of events of interest in patients receiving etanercept across approved indications. K. B. Gordon, A. B. Gottlieb, E. H. Giannini, P. J. Mease, J. Li, E. Chi, Y. Chon, H. H. Weng, S. Hamza, J. Wajdula, S. R. Stevens S. L. Lin Arthritis Rheum, 56 399-400 (), 2007. 2007
Preliminary Evidence for Sustained Bioactivity of IL-1 Trap (Rilonacept), A Long Acting IL-I Inhibitor, In Systemic Juvenile Idiopathic Arthritis (SJIA). E. H. Giannini, Y. Kimura, S. Li, P. J. Hashkes, A. O. Reiff, C. A. Wallace, K. B. Onel, Yi Wei, W. Fury, D. R. Nadler, S. Biedermann, G. Osgood, J. H. Papadopoulos A. R. Radin Arthritis Rheum, 56 514-515 (), 2007. 2007
The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis. E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. O. Reiff, G. Higgins, Y. Chon S. L. Lin Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 81 (), 2007. 2007
The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis. E. H. Giannini, N. T. Ilowite D. J. Lovell Ann Rheum Dis, 66 550 (), 2007. 2007
Efficacy of Abatacept in Different Sub-populations of Juvenile Idiopathic Arthritis (JIA): Results of a Randomized Withdrawal Study. E. H. Giannini, N. Ruperto, A. M. Prieur, E. Paz, N. E. Rubio-Perez, C. A. Silva, C. Abud, R. Burgos-Vargas, V. Gerloni, J. Melo-Gomes, C. S. Magalhaes, F. Sztajnbok, C. Goldstein-Schainberg, M. Scheinberg, P. Hashkes, C. Hom, L. H. Sigal, A. J. Block, A. Covucci, D. J. Lovell A. Martini Arthritis Rheum, 56 291 (), 2007. 2007
Adalimumab is Safe and Effective During Long-term Treatment of Patients with Juvenile Rheumatoid Arthritis: Results from a 2-Year Study. D. J. Lovell, N. Ruperto, S. Goodman, A. Reiff, D. Nemcova, A. M. Prieur, R. Joos, V. Gerloni, J. Bohnsack, L. Wagner-Weiner, H. I. Huppertz, N. Olson, M. McIlraith, J. Medich, E. H. Giannini A. Martini Arthritis Rheum, 56 292 (), 2007. 2007
Adalimumab for the Treatment of Patients with Juvenile Rheumatoid Arthritis: Safety and Efficacy After Conversion from Body Surface Area-Dosing to Weight-Based Fixed Dosing. D. J. Lovell, N. Ruperto, S. Goodman, A. O. Reiff, L. Jung, K. Jarosova, C. Sandborg, I. Foeldvari, J. Rovensky, K. Minden, R. Vehe, G. Horneff, M. McIlraith, J. R. Medich, E. H. Giannini A. Martini Arthritis Rheum, 56 373-374 (), 2007. 2007
Abatacept Treatment of Juvenile Idiopathic Arthritis (JIA): Safety Report. D. J. Lovell, N. Ruperto, A. M. Prieur, E. Paz, N. Rubio-Perez, C. Abud, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. S. Magalhaes, F. Sztajnbok, C. Goldenstein-Schainberg, M. Scheinberg, P. Hashkes, C. Hom, L. H. Sigal, A. J. Block, A. Covucci, P. L. N. Cornet, E. H. Giannini, A. Martini, A. Silva L. Pagliaro Arthritis Rheum, 56 292 (), 2007. 2007
Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long-acting IL-1 inhibitor in systemic juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini, Y. Kimura, A. O. Reiff, S. Li, P. J. Hashkes, C. A. Wallace, K. B. Onel, D. R. Nadler, S. A. Biedermann, K. G. Osgood, J. H. Papadopoulos A. R. Radin Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 86 (), 2007. 2007
Safety and efficacy of over 8 years of continuous etanercept (Enbrel) therapy in patients with juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini, C. A. Wallace, N. T. Ilowite, A. O. Reiff, Y. Chon, S. L. Lin S. W. Baumgartner Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 229 (), 2007. 2007
Safety over 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini C. A. Wallace Ann Rheum Dis, 66 112 (), 2007. 2007
Safety and Efficacy of Over 8 Years of Continuous Etanercept (Enbrel) Therapy in Patients With Juvenile Rheumatoid Arthritis. A. O. Reiff, D. J. Lovell, N. T. Ilowite, C. A. Wallace, Y. Chon, S. L. Lin, S. W. Baumgartner E. H. Giannini Arthritis Rheum, 56 292-293 (), 2007. 2007
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of a double-blind withdrawal phase. A. J. Block, N. Ruperto, D. J. Lovell, E. H. Giannini A. Martini Rheumatology, 46 i9-i10 (), 2007. 2007
Modulation of inflammatory disease markers after the initiation of infliximab plus methotrexate therapy in patients with juvenile rheumatoid arthritis. V. Visvananthan, J. C. Marini, D. J. Lovell, E. H. Giannini C. Wagner Ann Rheum Dis, 65 467-468 (), 2006. 2006
48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA). N. Ruperto, D. J. Lovell, S. Goodman E. H. Giannini Ann Rheum Dis, 65 56 (), 2006. 2006
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). N. Ruperto, D. J. Lovell, A. M. Prieur E. H. Giannini Ann Rheum Dis, 65 248 (), 2006. 2006
A phase IV registry of etanercept in children with juvenile rheumatoid arthritis. E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. Reiff, T. Bevirt, C. Y. Chen W. H. Tsuji Ann Rheum Dis, 65 253-254 (), 2006. 2006
Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of the double-blind withdrawal phase. E. H. Giannini, N. Ruperto, A. M. Prieur, E. Paz, N. E. R. Perez, C. A. Silva, C. A. Mendoza, R. Burgos-Vargas, C. Saad-Magalhaes, J. A. Melo-Gomes, V. Gerloni, F. Sztajnbok, M. Scheinberg, L. H. Sigal, A. J. Block, A. Covucci, P. L. N. Cornet, L. Pagliaro, D. J. Lovell A. Martini Arthritis Rheum, 54 4033 (), 2006. 2006
Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results. D. J. Lovell, N. Ruperto, L. Jung, A. O. Reiff, D. Nemcova, K. Jarosova, A. M. Prieur, C. Sandborg, J. Rovensky, J. Bohnsack, K. Minden, L. Wagner-Weiner, R. Vehe, G. Horneff, J. Medich, E. H. Giannini A. Martini Arthritis Rheum, 54 S303 (), 2006. 2006
Assessment of open-label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). D. J. Lovell, N. Ruperto, A. M. Prieur, E. Paz, N. E. R. Perez, C. A. Silva, C. A. Mendoza, R. Burgos-Vargas, C. Magalhaes, J. A. Melo-Gomez, V. Gerloni, F. R. Sztajnbok, M. Scheinburg, L. H. Sigal, A. J. Block, A. Covucci, P. L. N. Cornet, L. Pagliaro, E. H. Giannini A. Martini Arthritis Rheum, 54 S326 (), 2006. 2006
Preliminary evidence for bioactivity of IL-1 Trap (Rilonacept), a long-acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). D. J. Lovell, E. H. Giannini, Y. Kimura, S. Li, P. J. Hashkes, A. O. Reiff, C. A. Wallace, K. B. Onel, D. R. Nadler, J. R. Rosenberg, K. G. Osgood, J. H. Papadopoulos A. R. Radin Arthritis Rheum, 54 S325 (), 2006. 2006
Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long-acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. D. J. Lovell, E. H. Giannini, Y. Kimura A. Radin Ann Rheum Dis, 65 693 (), 2006. 2006
The effect of infliximab on the modulation of inflammatory disease markers in patients with juvenile rheumatoid arthritis. V. Visvananthan, E. H. Giannini C. Wagner Arthritis Rheum, 52 S86 (), 2005. 2005
Randomized trial of infliximab (IFX) plus methotrexate (MTX) for the treatment of polyarticular juvenile rheumatoid arthritis (JRA). N. Ruperto, D. J. Lovell, E. H. Giannini A. Martini Ann Rheum Dis, 64 511 (), 2005. 2005
Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients. N. Ruperto, D. J. Lovell, E. H. Giannini A. Martini Clin Exp Rheumatol, 23 S67 (), 2005. 2005
Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients. D. J. Lovell, N. Ruperto, A. Martini E. H. Giannini Arthritis Rheum, 52 S724 (), 2005. 2005
Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA). E. H. Giannini, D. J. Lovell, N. T. Ilowite, C. A. Wallace, L. E. Schanberg, J. Veith W. Tsuji Arthritis Rheum, 50 S90 (), 2004. 2004
Study outcomes for etanercept therapy in children with and adolescents with juvenile rheumatoid arthritis (JRA): Update from the pediatric registry. E. H. Giannini, D. J. Lovell, J. Veith W. Tsuji Clin Exp Rheumatol, 22 523 (), 2004. 2004
Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis (JIA). D. J. Lovell, N. Ruperto, S. Goodman, A. Reiff, A. Martini, E. H. Giannini, A. R. Radin, V. S. Rao G. Spencer-Green Arthritis Rheum, 50 S436 (), 2004. 2004
Long-term safety and efficacy experience with etanercept (Enbrel) in children with polyarticular juvenile rheumatoid arthritis. D. J. Lovell, A. Reiff, O. Y. Jones, R. Schneider, E. H. Giannini, J. B. Whitmore B. White Arthritis Rheum, 50 S436 (), 2004. 2004
Etanercept therapy in children with juvenile rheumatoid arthritis: Four year outcome. D. J. Lovell E. H. Giannini Clin Exp Rheumatol, 22 522 (), 2004. 2004
Preliminary defintions of improvement for juvenile myositis. L. Rider, E. H. Giannini H. I. Brunner Arthritis Rheum, 48 S433 (), 2003. 2003
Neoral registry in polyarticular juvenile rheumatoid arthritis. E. H. Giannini, N. Ruperto, A. L. Tomasi, V. Gerloni, R. Hafner S. Nielson Pediatr Rheumatol, 1 3 (), 2003. 2003
Etanercept/methotrexate registry in juvenile rheumatoid arthritis (JRA). E. H. Giannini, D. J. Lovell, T. M. Sherrard, N. T. Ilowite A. Reiff Pediatr Rheumatol, 1 3 (), 2003. 2003
International consensus for core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part I: Juvenile Systemic Lupus Erythematosus (JSLE). N. Ruperto, K. J. Murray, A. Ravelli, D. J. Lovell, E. H. Giannini A. Martini Arthritis Rheum, 44 S294 (), 2001. 2001
International consensus for the core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part II: Juvenile Dermatomyositis (JDM). N. Ruperto, A. Ravelli, K. J. Murray, E. H. Giannini, D. J. Lovell A. Martini Arthritis Rheum, 44 S261 (), 2001. 2001
Sustained safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini, M. Lange, D. Burge B. K. Finck Ann Rheum Dis, 59 724 (), 2000. 2000
Safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini, M. Lange, D. Burge B. K. Finck Arthritis Rheum, (), 1999. 1999
Tumor necrosis factor (P75) receptor Fc fusion protein, TNFR:FC, (Enbrel) in children with polyarticular course juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini, M. Lange, L. Soffes B. K. Finck AAP, S24 (), 1998. 1998
Safety and Efficacy of tumor necrosis factor receptor P75 Fc fusion protein (TNF:FC, Enbrel) in polyarticular course juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini, J. B. Whitmore, L. Soffes B. K. Finck Arthritis Rheum, 41 S130 (), 1998. 1998
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis I: Outcome status. N. Ruperto, J. E. Levinson, A. Ravelli, E. S. Shear, B. L. Tague, K. Tague, K. Murray A. Martini Arthritis Rheum, 39 S56 (), 1996. 1996
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis II: Early predictors of outcome. N. Ruperto, A. Revelli, J. E. Levinson, E. S. Shear, K. Murray, B. L. Tague, A. Martini, D. N. Glass E. H. Giannini Arthritis Rheum, 39 S56 (), 1996. 1996
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis II: Early predictors of outcome. E. H. Giannini, N. Ruperto, A. Ravelli, E. S. Shear, B. L. Tague, K. Murray, J. E. Levinson, A. Martini D. N. Glass Clin Exp Rheumatol, 39 S56 (), 1996. 1996
Preliminary definition of improvement in juvenile arthritis. E. H. Giannini, N. Ruperto, A. Ravelli, D. J. Lovell A. Martini Arthritis Rheum, 39 S56 (), 1996. 1996
Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: A double-blind, placebo-controlled pilot study. E. H. Giannini, E. D. Silverman, D. J. Lovell, R. P. Sundel, B. L. Tague N. Ruperto Clin Exp Rheumatol, 13 560 (), 1995. 1995
Validation and rater reliability of the childhood myositis assessment scale (C-MAS). D. J. Lovell, E. H. Giannini, L. Rider, J. Hicks, M. Smith, R. Rennebohm C. Lindsley Arthritis Rheum, 38 S183 (), 1995. 1995
Intravenous immune globulin in polyarticular JRA: Results of a phase I/II trial. E. H. Giannini, D. J. Lovell, E. D. Silverman R. P. Sundel Arthritis Rheum, 37 S276 (), 1994. 1994
Preliminary core set of outcome variables for use in JRA clinical trials. E. H. Giannini, D. J. Lovell, D. T. Felson C. H. Goldsmith Arthritis Rheum, 37 S428 (), 1994. 1994
Redundancy of conventional outcome variables used in JRA clinical trials. E. H. Giannini D. J. Lovell Arthritis Rheum, 37 S238 (), 1994. 1994
Low-dose methotrexate in children with JRA: Results of a post-trial, long-term follow-up program. E. H. Giannini, A. J. Newman C. W. Fink Arthritis Rheum, 36 S54 (), 1993. 1993
Intravenous immune globulin in systemic JRA. E. D. Silverman, E. H. Giannini G. Cawkwell Arthritis Rheum, 36 S59 (), 1993. 1993
Results of the auranofin long-term follow-up program (AU 109X) in children with juvenile rheumatoid arthritis. E. H. Giannini J Rheumatol, 19 114 (), 1992. 1992
Low-dose methotrexate treatment of recalcitrant JRA: Results of the USA-USSR randomized, controlled trial. E. H. Giannini, E. J. Brewer, A. Shaikov, N. Kuzmina A. Maximov Arthritis Rheum, S53 S53 (), 1991. 1991
Meta-analysis of anti-rheumatic drug trials in juvenile rheumatoid arthritis. E. H. Giannini, A. Shaikov, A. Maximov, N. Kuzmina E. J. Brewer Arthritis Rheum, 34 S152 (), 1991. 1991
Ibuprofen suspension in the treatment of JRA: Results of a double-blind, aspirin-controlled trial. E. H. Giannini, E. J. Brewer, M. L. Scheinbaum, L. A. Alexander R. L. Copp Arthritis Rheum, 32 R39 (), 1989. 1989
Methotrexate in the treatment of recalcitrant JRA: Results of a double-blind, placebo-controlled, randomized trial. E. H. Giannini E. J. Brewer Arthritis Rheum, 32 S82 (), 1989. 1989
HLA B27-associated arthritis in childhood: Long-term clinical and diagnostic outcomes. K. A. Sheerin, E. H. Giannini E. J. Brewer J Allergy Clin Immunol, 81 518 (), 1988. 1988
Auranofin in the treatment of juvenile rheumatoid arthritis: Results of the USA-USSR, double-blind, placebo-controlled trial. E. J. Brewer, N. Kusmina E. H. Giannini Arthritis Rheum, 31 S26 (), 1988. 1988
Auranofin in the treatment of juvenile rheumatoid arthritis: Results of the USA-USSR, double-blind, placebo-controlled trial. C. W. Fink, E. J. Brewer, N. Kusmina E. H. Giannini SEAPAL, (), 1988. 1988
Oral gold (auranofin) in juvenile rheumatoid arthritis (JRA): Results of a double-blind placebo-controlled trial. E. J. Brewer E. H. Giannini Arthritis Rheum, 30 S31 (), 1987. 1987
Changes in the erythrocyte sedimentation rate correlate poorly with articular disease activity in JRA. E. H. Giannini E. J. Brewer J Rheumatol, 13 976 (), 1986. 1986
Long-term usage of oral gold (auranofin) in the treatment of children with juvenile rheumatoid arthritis (JRA). X. He, E. H. Giannini E. J. Brewer ILAR, 105 (), 1985. 1985
D-penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of a double-blind, placebo-controlled trial. E. J. Brewer, E. H. Giannini, N. Kuzmina L. Alekseev Arthritis Rheum, 28 S14 (), 1985. 1985
D-penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of a double-blind, placebo-controlled trial. E. J. Brewer, E. H. Giannini, N. Kuzmina L. Alekseev ILAR, 50 (), 1985. 1985
Auranofin in the long-term treatment of children with juvenile rheumatoid arthritis. E. H. Giannini, E. J. Brewer X. He Clin Res, 33 919a (), 1985. 1985
Generalizations from multiple studies of non-steroidal anti-inflammatory drugs(NSAIDs) in children with juvenile rheumatoid arthritis (JRA). E. H. Giannini E. J. Brewer Clin Res, 33 918a (), 1985. 1985
Characteristics of responders (R) and non-responders (NR) to slower-acting anti-rheumatic drugs (SAARDs) in juvenile rheumatoid arthritis (JRA). E. H. Giannini E. J. Brewer Arthritis Rheum, 28 S56 (), 1985. 1985
Joint hypermobility in juvenile episodic arthritis/arthralgia (JEA). A. Gedalia, E. J. Brewer, E. H. Giannini D. A. Person ILAR, 133 (), 1985. 1985
Early clinical indicators of eventual response to non-steroidal anti-inflammatory drugs (NSAIDs) in patients with juvenile rheumatoid arthritis (JRA). D. J. Lovell, E. H. Giannini, E. J. Brewer D. A. Person J Rheumatol, 11 716 (), 1984. 1984
Serial determinations of circulating immune complexes (CIC) in the sera of children with rheumatic disease. D. A. Person, G. J. Buffone, C. M. Leatherwood, E. J. Brewer E. H. Giannini Pediatr Res, 18 306 (), 1984. 1984
Joint hypermobility in juvenile episodic arthritis/arthralgia (JEA). A. Gedalia, D. A. Person, E. H. Giannini E. J. Brewer Clin Res, 32 821a (), 1984. 1984
Blood gold concentrations in children with juvenile rheumatoid arthritis. E. J. Brewer, E. H. Giannini D. A. Person Arthritis Rheum, 26 S58 (), 1983. 1983
Auranofin in juvenile rheumatoid arthritis. E. H. Giannini, E. J. Brewer D. A. Person Pediatr Res, 17 419 (), 1983. 1983
Cooperative multicentered clinical trial with the USSR: Advantages and difficulties. E. H. Giannini E. J. Brewer Control Clin Trials, 4 151 (NIL), 1983. 1983
Time course response to non-steroidal anti-inflammatory drugs in patients with juvenile rheumatoid arthritis. D. J. Lovell, E. H. Giannini, E. J. Brewer D. A. Person Clin Res, 31 918a (), 1983. 1983
Immune complexes in the sera of patients with rheumatic disease. D. A. Person, C. M. Leatherwood, G. J. Buffone, E. H. Giannini, K. S. Barron E. J. Brewer Pediatr Res, 17 418 (), 1983. 1983
Children at risk of developing ankylosing spondylitis. K. S. Barron, E. J. Brewer E. H. Giannini Arthritis Rheum, 25 S151 (), 1982. 1982
Auranofin in juvenile rheumatoid arthritis. E. H. Giannini, E. J. Brewer D. A. Person Arthritis Rheum, 25 S17 (), 1982. 1982
Immune complexes in the sera of pediatric patients with rheumatic disease. D. A. Person, C. M. Leatherwood, G. J. Buffone, E. H. Giannini, K. S. Barron E. J. Brewer Pediatr Res, 16 229a (), 1982. 1982
Psychosocial functioning in children with juvenile rheumatoid arthritis (JRA). J. Ivey, E. J. Brewer E. H. Giannini Arthritis Rheum, 24 100 (), 1981. 1981
Pirprofen in the treatment of juvenile rheumatoid arthritis: A segment I study. E. J. Brewer, J. C. Bass, E. H. Giannini, B. H. Athreya, D. P. Goldsmith, N. Brandstrup, J. J. Miller L. M. Pachman ILAR, 76 (), 1981. 1981
Proquazone in the treatment of juvenile rheumatoid arthritis: A segment I study. E. J. Brewer, E. H. Giannini, J. Baum, C. W. Fink, V. Hanson, J. C. Jacobs J. G. Schaller ILAR, STP6 215 (), 1981. 1981
A comparative study of the epidemiologic and clinical natural histories of juvenile rheumatoid arthritis. E. J. Brewer E. H. Giannini Arthritis Rheum, 23 656 (), 1980. 1980
Anti-eye antibody in juvenile rheumatoid arthritis. D. A. Person, C. M. Leatherwood, E. J. Brewer, E. H. Giannini K. S. Barron Clin Res, 28 863a (), 1980. 1980